| Symbol | PHIO |
|---|---|
| Name | PHIO PHARMACEUTICALS CORP. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 257 SIMARANO DRIVE,SUITE 101, MARLBOROUGH, Massachusetts, 01752, United States |
| Telephone | +1 508 767-3861 |
| Fax | — |
| — | |
| Website | https://www.phiopharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001533040 |
| Description | Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The companys pipeline products include PH-762, PH-804, PH-790, and others. Additional info from NASDAQ: |
New Form ARS - Phio Pharmaceuticals Corp. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001683168-26-006475 <b>Size:</b> 1 MB
Read moreNew Form DEFA14A - Phio Pharmaceuticals Corp. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001683168-26-006474 <b>Size:</b> 1 MB
Read moreNew Form DEF 14A - Phio Pharmaceuticals Corp. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001437749-26-027997 <b>Size:</b> 2 MB
Read morePhio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894
Read morePhio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
Read moreNew Form 3 - Phio Pharmaceuticals Corp. <b>Filed:</b> 2026-07-30 <b>AccNo:</b> 0001683168-26-005842 <b>Size:</b> 14 KB
Read moreCorrection to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Read morePhio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Read more(70% Positive) PHIO PHARMACEUTICALS CORP. (PHIO) Provides Update on experience for drug development
Read morePhio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
Read more